- Report
- March 2020
- 137 Pages
Global
From €4657EUR$4,899USD£3,913GBP
- Report
- November 2023
- 215 Pages
Global
From €4866EUR$5,298USD£3,950GBP
- Report
- January 2024
- 213 Pages
Global
From €4421EUR$4,650USD£3,714GBP
- Report
- September 2022
- 110 Pages
Global
From €5229EUR$5,500USD£4,393GBP
- Report
- February 2024
- 202 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- October 2022
- 194 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- November 2022
- 125 Pages
Global
From €2367EUR$2,490USD£1,989GBP
- Report
- April 2021
- 377 Pages
Global
From €3798EUR$3,995USD£3,191GBP
- Report
- December 2022
- 77 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- January 2023
- 343 Pages
Global
From €3327EUR$3,500USD£2,795GBP
€4753EUR$5,000USD£3,993GBP
- Report
- August 2021
- 77 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- January 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
From €1901EUR$2,000USD£1,597GBP
- Report
- November 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 189 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- August 2023
- 114 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2024
- 159 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- February 2024
- 187 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- March 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP

The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less Read more